AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.56-0.12 (-0.11%) ▼|ACN226.79+1.87 (+0.83%) ▲|ADBE245.41-6.26 (-2.49%) ▼|AMAT416.22-13.79 (-3.21%) ▼|AMD540.97-21.26 (-3.78%) ▼|AMGN435.21+1.18 (+0.27%) ▲|AMT184.49+3.13 (+1.73%) ▲|AMZN253.39-1.37 (-0.54%) ▼|AVGO333.96-10.37 (-3.01%) ▼|AXP316.28+2.41 (+0.77%) ▲|BA189.00+0.27 (+0.14%) ▲|BAC52.14+0.44 (+0.85%) ▲|BKNG165.75-0.06 (-0.03%) ▼|BLK1,135.44+14.66 (+1.31%) ▲|BMY60.60+0.03 (+0.05%) ▲|BNY143.30+1.21 (+0.85%) ▲|BRK-B529.60+3.92 (+0.74%) ▲|C125.41+2.20 (+1.78%) ▲|CAT737.56+1.92 (+0.26%) ▲|CL93.70+1.03 (+1.11%) ▲|CMCSA22.25+0.48 (+2.18%) ▲|COF201.81+2.95 (+1.48%) ▲|COP144.70+2.97 (+2.10%) ▲|COST990.58+12.57 (+1.29%) ▲|CRM239.28-7.46 (-3.02%) ▼|CSCO108.10-1.76 (-1.60%) ▼|CVS92.88+0.30 (+0.32%) ▲|CVX222.51+3.19 (+1.45%) ▲|DE641.25-9.42 (-1.45%) ▼|DHR230.18-1.33 (-0.57%) ▼|DIS111.59+0.91 (+0.82%) ▲|DUK120.86+1.98 (+1.67%) ▲|EMR161.70-0.45 (-0.28%) ▼|FDX292.73-2.82 (-0.95%) ▼|GD341.67+4.64 (+1.38%) ▲|GE317.07+5.07 (+1.63%) ▲|GEV928.95+2.51 (+0.27%) ▲|GILD156.37-1.00 (-0.64%) ▼|GM84.92+1.26 (+1.51%) ▲|GOOG339.95-4.96 (-1.44%) ▼|GOOGL343.72-5.50 (-1.57%) ▼|GS890.30-0.98 (-0.11%) ▼|HD312.36+4.12 (+1.34%) ▲|HON211.93+1.43 (+0.68%) ▲|IBM231.76-2.36 (-1.01%) ▼|INTC91.16-4.22 (-4.42%) ▼|INTU323.04-7.13 (-2.16%) ▼|ISRG429.27+1.41 (+0.33%) ▲|JNJ255.45+2.17 (+0.85%) ▲|JPM341.07+5.54 (+1.65%) ▲|KO93.38+1.38 (+1.50%) ▲|LIN498.82+5.60 (+1.14%) ▲|LLY1,262.18+10.57 (+0.84%) ▲|LMT544.12+11.48 (+2.16%) ▲|LOW198.24+2.52 (+1.29%) ▲|LRCX268.61-8.86 (-3.19%) ▼|MA617.04+0.72 (+0.12%) ▲|MCD243.43+0.93 (+0.38%) ▲|MDLZ64.12+1.09 (+1.73%) ▲|MDT94.70-0.75 (-0.79%) ▼|META720.00-16.72 (-2.27%) ▼|MMM164.77-0.57 (-0.34%) ▼|MO74.76+0.92 (+1.24%) ▲|MRK146.74+1.55 (+1.07%) ▲|MS182.61+0.51 (+0.28%) ▲|MSFT528.56-10.88 (-2.02%) ▼|MU895.72-35.52 (-3.81%) ▼|NEE79.92+0.96 (+1.22%) ▲|NFLX70.82-1.79 (-2.47%) ▼|NKE37.44+0.30 (+0.81%) ▲|NOW140.11-8.46 (-5.69%) ▼|NVDA217.01-0.22 (-0.10%) ▼|ORCL129.62-4.86 (-3.61%) ▼|PEP131.21+2.83 (+2.20%) ▲|PFE29.59+0.15 (+0.49%) ▲|PG159.22+2.14 (+1.36%) ▲|PLTR187.33-13.18 (-6.57%) ▼|PM204.24+4.34 (+2.17%) ▲|QCOM176.07-2.33 (-1.31%) ▼|RTX191.39+4.44 (+2.38%) ▲|SBUX97.08+0.20 (+0.20%) ▲|SCHW92.40-1.76 (-1.87%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.92+1.53 (+0.75%) ▲|T23.64+0.14 (+0.57%) ▲|TMO686.16-10.33 (-1.48%) ▼|TMUS158.50+1.47 (+0.94%) ▲|TSLA358.11-4.33 (-1.20%) ▼|TXN281.87+2.75 (+0.99%) ▲|UBER70.67-0.61 (-0.85%) ▼|UNH400.94-5.74 (-1.41%) ▼|UNP287.74-0.98 (-0.34%) ▼|UPS97.28-0.55 (-0.56%) ▼|USB58.40+1.01 (+1.76%) ▲|V402.47+2.72 (+0.68%) ▲|VZ44.74+0.34 (+0.75%) ▲|WFC83.79+1.04 (+1.26%) ▲|WMT118.37+0.50 (+0.42%) ▲|XOM176.64+1.96 (+1.12%) ▲|AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.56-0.12 (-0.11%) ▼|ACN226.79+1.87 (+0.83%) ▲|ADBE245.41-6.26 (-2.49%) ▼|AMAT416.22-13.79 (-3.21%) ▼|AMD540.97-21.26 (-3.78%) ▼|AMGN435.21+1.18 (+0.27%) ▲|AMT184.49+3.13 (+1.73%) ▲|AMZN253.39-1.37 (-0.54%) ▼|AVGO333.96-10.37 (-3.01%) ▼|AXP316.28+2.41 (+0.77%) ▲|BA189.00+0.27 (+0.14%) ▲|BAC52.14+0.44 (+0.85%) ▲|BKNG165.75-0.06 (-0.03%) ▼|BLK1,135.44+14.66 (+1.31%) ▲|BMY60.60+0.03 (+0.05%) ▲|BNY143.30+1.21 (+0.85%) ▲|BRK-B529.60+3.92 (+0.74%) ▲|C125.41+2.20 (+1.78%) ▲|CAT737.56+1.92 (+0.26%) ▲|CL93.70+1.03 (+1.11%) ▲|CMCSA22.25+0.48 (+2.18%) ▲|COF201.81+2.95 (+1.48%) ▲|COP144.70+2.97 (+2.10%) ▲|COST990.58+12.57 (+1.29%) ▲|CRM239.28-7.46 (-3.02%) ▼|CSCO108.10-1.76 (-1.60%) ▼|CVS92.88+0.30 (+0.32%) ▲|CVX222.51+3.19 (+1.45%) ▲|DE641.25-9.42 (-1.45%) ▼|DHR230.18-1.33 (-0.57%) ▼|DIS111.59+0.91 (+0.82%) ▲|DUK120.86+1.98 (+1.67%) ▲|EMR161.70-0.45 (-0.28%) ▼|FDX292.73-2.82 (-0.95%) ▼|GD341.67+4.64 (+1.38%) ▲|GE317.07+5.07 (+1.63%) ▲|GEV928.95+2.51 (+0.27%) ▲|GILD156.37-1.00 (-0.64%) ▼|GM84.92+1.26 (+1.51%) ▲|GOOG339.95-4.96 (-1.44%) ▼|GOOGL343.72-5.50 (-1.57%) ▼|GS890.30-0.98 (-0.11%) ▼|HD312.36+4.12 (+1.34%) ▲|HON211.93+1.43 (+0.68%) ▲|IBM231.76-2.36 (-1.01%) ▼|INTC91.16-4.22 (-4.42%) ▼|INTU323.04-7.13 (-2.16%) ▼|ISRG429.27+1.41 (+0.33%) ▲|JNJ255.45+2.17 (+0.85%) ▲|JPM341.07+5.54 (+1.65%) ▲|KO93.38+1.38 (+1.50%) ▲|LIN498.82+5.60 (+1.14%) ▲|LLY1,262.18+10.57 (+0.84%) ▲|LMT544.12+11.48 (+2.16%) ▲|LOW198.24+2.52 (+1.29%) ▲|LRCX268.61-8.86 (-3.19%) ▼|MA617.04+0.72 (+0.12%) ▲|MCD243.43+0.93 (+0.38%) ▲|MDLZ64.12+1.09 (+1.73%) ▲|MDT94.70-0.75 (-0.79%) ▼|META720.00-16.72 (-2.27%) ▼|MMM164.77-0.57 (-0.34%) ▼|MO74.76+0.92 (+1.24%) ▲|MRK146.74+1.55 (+1.07%) ▲|MS182.61+0.51 (+0.28%) ▲|MSFT528.56-10.88 (-2.02%) ▼|MU895.72-35.52 (-3.81%) ▼|NEE79.92+0.96 (+1.22%) ▲|NFLX70.82-1.79 (-2.47%) ▼|NKE37.44+0.30 (+0.81%) ▲|NOW140.11-8.46 (-5.69%) ▼|NVDA217.01-0.22 (-0.10%) ▼|ORCL129.62-4.86 (-3.61%) ▼|PEP131.21+2.83 (+2.20%) ▲|PFE29.59+0.15 (+0.49%) ▲|PG159.22+2.14 (+1.36%) ▲|PLTR187.33-13.18 (-6.57%) ▼|PM204.24+4.34 (+2.17%) ▲|QCOM176.07-2.33 (-1.31%) ▼|RTX191.39+4.44 (+2.38%) ▲|SBUX97.08+0.20 (+0.20%) ▲|SCHW92.40-1.76 (-1.87%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.92+1.53 (+0.75%) ▲|T23.64+0.14 (+0.57%) ▲|TMO686.16-10.33 (-1.48%) ▼|TMUS158.50+1.47 (+0.94%) ▲|TSLA358.11-4.33 (-1.20%) ▼|TXN281.87+2.75 (+0.99%) ▲|UBER70.67-0.61 (-0.85%) ▼|UNH400.94-5.74 (-1.41%) ▼|UNP287.74-0.98 (-0.34%) ▼|UPS97.28-0.55 (-0.56%) ▼|USB58.40+1.01 (+1.76%) ▲|V402.47+2.72 (+0.68%) ▲|VZ44.74+0.34 (+0.75%) ▲|WFC83.79+1.04 (+1.26%) ▲|WMT118.37+0.50 (+0.42%) ▲|XOM176.64+1.96 (+1.12%) ▲|
18.5 C
New York
Friday, October 16, 2026

Tag: arm

newssourceFORcompanycontentinformation1releasesmarket

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

THE HOME DEPOT DONATES $250,000 TO SUPPORT YOUTH PROGRAMS ACROSS GREATER LOS ANGELES AHEAD OF U.S. MEN’S NATIONAL TEAM’S WORLD CUP OPENER

Donation to Boys & Girls Clubs of America will support soccer programming, workforce development and other initiatives serving youth across Southern CaliforniaATLANTA, June 12,...

THE HOME DEPOT DONATES $250,000 TO SUPPORT YOUTH PROGRAMS ACROSS GREATER LOS ANGELES AHEAD OF U.S. MEN’S NATIONAL TEAM’S WORLD CUP OPENER

Donation to Boys & Girls Clubs of America will support soccer programming, workforce development and other initiatives serving youth across Southern CaliforniaATLANTA, June 12,...

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —

The Truth About Global Brands

Truth Is Everything: 72% of People Say It's More Important than Ever to Prioritize TruthResearch from McCann and Economist Enterprise reveals global growth will be driven by brands' ability to eliminate doubt and connect with the...

Water Sports Foundation’s Top Tips for Boosting the Fun Factor When Boating with Kids

Experts Share Advice on How to Keep Kids Engaged and Enjoying Family Time on the WaterORLANDO, Fla., June 11, 2026 /PRNewswire/ -- Family boating adventures...

M&T Bank and The Florida Bar Renew Relationship to Expand Access to the M&T Bank Nota Platform

Enhanced platform reflects continued momentum, user-informed innovation and growing adoption among attorneysBUFFALO, N.Y. and TALLAHASSEE, Fla., June 11, 2026 /PRNewswire/ -- M&T Bank (NYSE:MTB)...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsArm

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers